Salem Partners, LLC - Investment Banking and Wealth Management
  • Home
  • About
  • Investment Banking
    • Valuation Services
    • Media & Entertainment
    • Healthcare & Life Sciences
    • Industrials
    • Real Estate
    • Specialty & Lender Finance
    • Transactions
  • Wealth Management
    • Portfolio Log In
  • Real Estate Development
  • Professionals
  • News
  • Contact

Onconano Medicine Lands $50m in Series B to Spur Nanosensor that 'Lights Up' Cancer

6/22/2021

 
Picture
Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue. This is intended to make it easier for surgeons to remove cancer cells while leaving healthy, functional tissue intact.

The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)

OncoNano Medicine Raises ~$50 Million in Series B Financing

6/17/2021

 
Picture
OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross-border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology...(read more)

Femasys Inc. Announces Pricing of Initial Public Offering

6/17/2021

 
Picture
Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The gross proceeds to Femasys from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $34.45 million. All of the shares are being offered by Femasys. In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital Market on June 18, 2021, under the ticker symbol “FEMY.” The offering is expected to close on June 22, 2021, subject to customary closing conditions...(read more)

    News

    All
    Aerospace & Defense
    Healthcare & Life Sciences
    Industrials
    Investment Banking
    Media & Entertainment
    Real Estate
    Specialty & Lender Finance
    Wealth Management

    Archives

    December 2022
    April 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    February 2021
    December 2020
    August 2020
    November 2019
    August 2019
    July 2019
    December 2018
    November 2018
    September 2018
    July 2018
    June 2018
    May 2018
    April 2018
    January 2018
    November 2017
    July 2017
    February 2017
    December 2016
    November 2016
    October 2016
    July 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    December 2014
    October 2014
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014
    November 2013
    October 2013
    February 2013
    December 2012
    October 2012
    February 2012
    January 2012
    December 2011
    September 2011
    August 2011
    June 2011
    January 2010
    December 2009
    November 2009
    August 2009
    June 2009
    February 2009
    September 2008
    August 2008
    July 2008
    June 2008
    May 2008
    April 2008
    February 2008
    December 2007
    July 2007
    May 2007
    February 2007
    January 2007
    December 2006
    November 2006
    October 2006

    RSS Feed

© 2016 by Salem Partners LLC - All Rights Reserved. Member FINRA/SIPC.
11111 Santa Monica Blvd. Suite 2250, Los Angeles, CA 90025
Salem Partners, LLC Form CRS